SG Americas Securities
PVLA

SG Americas Securities’s Palvella Therapeutics PVLA Stock Holding History

SG Americas Securities’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308K Sell
2,472
-217
-8% -$22.6K ﹤0.01% 2446
2025
Q4 		$281K Buy
+2,689
New +$229K ﹤0.01% 2785
2022
Q1 		– Sell
-230
Closed -$70K – 3529
2021
Q4 		$70K Buy
+230
New +$73.7K ﹤0.01% 3155
2020
Q3 		– Sell
-337
Closed -$84K – 3554
2020
Q2 		$84K Buy
337
+129
+62% +$30.2K ﹤0.01% 3433
2020
Q1 		$38K Buy
+208
New +$52.4K ﹤0.01% 3219
2019
Q1 		– Sell
-170
Closed -$36K – 3678
2018
Q4 		$36K Buy
+170
New +$52.7K ﹤0.01% 2868

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SG Americas Securities's PVLA Position: Q1 2026 in Review

SG Americas Securities reduced its Palvella Therapeutics (PVLA) stake by 8.1% in Q1 2026, selling an estimated $22.6K and leaving 2,472 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

SG Americas Securities first reported a position in PVLA in Q4 2018 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • SG Americas Securities held 2,472 shares of Palvella Therapeutics worth $308K as of Q1 2026.
  • SG Americas Securities sold 217 Palvella Therapeutics shares in Q1 2026, an estimated $22.6K.
  • Palvella Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2446 holding.
  • SG Americas Securities first reported a position in Palvella Therapeutics in Q4 2018 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.